Emerging therapies for clostridium difficile infection - Focus on fidaxomicin

Infection and Drug Resistance

Volumn 6, Issue , 2013, Pages 41-53

  Chaparro Rojas, Fredy ^a   Mullane, Kathleen M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CDAD; Clostridium difficile infection (CDI); Clostridium difficile associated diarrhea; Fidaxomicin; Metronidazole; Vancomycin

Indexed keywords

BACITRACIN; CADAZOLID; FIDAXOMICIN; FUSIDIC ACID; IMMUNOGLOBULIN G; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; RNA POLYMERASE; SUROTOMYCIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FECES TRANSPLANTATION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NAUSEA; PRACTICE GUIDELINE; RECURRENT DISEASE; RELAPSE; REVIEW; RNA SYNTHESIS; SIDE EFFECT; TASTE DISORDER;

EID: 84879916985     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S24434     Document Type: Review

References (102)

1. Cohen SH, Gerding DN, Johnson S, et al; For Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
2. Bartlett JG, Taylor NS, Chang T, Dzink J. Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr. 1980; 33(Suppl 11):2521-2526.
3. George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol. 1982;15(6):1049-1053.
4. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257-262.
5. Lucado J, Gould C, Elixhauser A. Clostridium Difficile Infections (CDI) in Hospital Stays, 2009. Healthcare Cost and Utilization Project Statistical Brief #124. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf. Accessed April 29, 2013.
6. Rafii F, Sutherland JB, Cerniglia CE. Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag. 2008;4(6):1343-1358.
7. Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile. Toxins (Basel). 2010;2(7):1848-1880.
8. Starr JM, Impallomeni M. Risk of diarrhoea, Clostridium difficile and cefotaxime in the elderly. Biomed Pharmacother. 1997;51(2): 63-67.
9. Barc MC, Depitre C, Corthier G, Collignon A, Su WJ, Bourlioux P. Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo. Antimicrob Agents Chemother. 1992;36(6):1332-1335.
10. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55 Suppl 2: S65-S70.
11. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(10): 1489-1492.
12. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53(5):440-447.
13. Bauer MP, Kuijper EJ, van Dissel JT; For European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067-1079.
14. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control. 1995;23(2):87-94.
15. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7):2403-2406.
16. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-307.
17. Louie TJGM, Grimard D, Johnson S, Poirier A, Weiss K; For the Tolevamer Study Group. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea [abstact K-425a]. 2007.
18. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5(9):549-557.
19. Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother. 2008;62(5):1046-1052.
20. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526-536.
21. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27(10):1169-1172.
22. Louie TJ, Miller MA, Mullane KM, et al; For OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-431.
23. Cornely OA, Crook DW, Esposito R, et al; For OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012; 12(4):281-289.
24. Patino HSC, Louie T, Bernardo P, Friedland I; For the CDI Study Group. Efficacy and safety of the lipopeptide CB-183,315 for the treatment of Clostridium difficile infection [Abstract K-205a]. Proceedings of the 51st Internatl Congr Antimicr Ag Chemother; September 17-20, 2011; Chicago, IL.
25. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58(6):403-410.
26. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775.
27. Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther. 2011;9(7):767-777.
28. Parenti F, Pagani H, Beretta G. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J Antibiot (Tokyo). 1975;28(4):247-252.
29. Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo). 1987;40(5): 567-574.
30. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother. 2011;55(11):5194-5199.
31. Biedenbach DJ, Ross JE, Putnam SD, Jones RN. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother. 2010;54(5):2273-2275.
32. Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo). 1975;28(4): 253-259.
33. Seddon JSP. Preliminary OPT-80 Mode of Action Studies. Optimer Pharmaceuticals, Inc. Report Number BIO090203A. 2003.
34. Sergio S, Pirali G, White R, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action. J Antibiot (Tokyo). 1975;28(7):543-549.
35. Srivastava A, Talaue M, Liu S, et al. New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr Opin Microbiol. 2011;14(5):532-543.
36. Sears PBF, Citron DM. Typing and Susceptibility of Bacterial Isolates from the OPT-80 (PAR-101) Phase 2A Study for C. difficile-associated Diarrhea. [Poster] 9th Biennial Congress of the Anaerobe Society of the Americas, Long Beach, CA; 2008.
37. Crook DW, Walker AS, Kean Y, et al; For Study 003/004 Teams. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55 Suppl 2:S93-S103.
38. Mullane KGY, Crook D, Cornely OA, Miller M, Louie T, Gorbach S. Renal Impairment and Response to Fidaxomicin versus Vancomycin in Patients with Clostridium difficile Infection [abstract]. Proceedings of the 49th Annual Infectious Diseases Society of America Meeting; October 20-23, 2011; Boston MA.
39. Cornely OAMM, Fantin B, Mullane K, Kean Y, Gorbach S. Clostridium difficile-associated diarrhea in cancer patients treated with fidaxomicin or vancomycin. Proceedings of the American Society of Clinical Oncology Abstract #9067; June 1-5, 2012; Chicago, IL.
40. Cornely OAMM, Fantin B, Mullane K, Kean Y, Gorbach S. Clinical outcomes for cancer patients with Clostridium difficile infection (CDI) Poster 2289. Proceedings of the European Congress of Clinical Microbiology and Infectious Diseases. March 31-April 3, 2012; London, UK.
41. Louie TJ, Miller MA, Crook DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc. 2013;61(2):222-230.
42. Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs. 2007;8(2):168-173.
43. Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother. 2011;55(9):4427-4429.
44. Sears P, Louie T, Mullane KM, et al. Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium Difficile infection (CDI). Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 12-15, 2009; San Francisco, CA.
45. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009;53(1):223-228.
46. Okumu FWR, Sears P, Shue YK. Safety and Pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). October 30-November 2, 2004; Washington, DC.
47. Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55 Suppl 2:S116-S120.
48. DIFICID® [prescribing information]. San Diego, CA: Optimer Pharmaceuticals, Inc; May 2011, Data on File. Clinical Study Report OPT-80-004 Final. June 4, 2010. Optimer Pharmaceuticals, Inc, Data on File. Clinical Study Report OPT-80-003 Final. June 17, 2010 (Version 2). Optimer Pharmaceuticals, Inc. Available from: http://www.drugs.com/comments/fidaxomicin/dificid.html. Accessed April 29, 2013.
49. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology. 2010;156(Pt 11):3354-3359.
50. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012; 55 Suppl 2:S121-S126.
51. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55 Suppl 2:S132-S142.
52. Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother. 2013;68(3):515-522.
53. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis. 2012;55 Suppl 2:S162-S169.
54. DIFICID ™ oral tablets, fidaxomicin oral tablets [prescribing information]. San Diego, CA: Optimer Pharmaceuticals, Inc; 2011.
55. Miller MAMK, Weiss K, Lentnek A, et al. Faster time to resolution of diarrhea with fidaxomicin vs vancomycin in patients with Clostridium difficile infection (CDI) [abstract]. Proceedings of the 47th Annual Infectious Diseases Society of America Meeting. October 29-November 1, 2009; Philadelphia, PA.
56. Drugs.com. User reviews for Dificid [webpage on the Internet]. Drugs.com; 2012. Available from: http://www.drugs.com/comments/fidaxomicin/dificid.html. Accessed December 28, 2012.
57. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43(4):421-427.
58. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin Infect Dis. 2009;48(4):e41-e46.
59. Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009;43(1):91-93.
60. Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract. 2011;2011:106978.
61. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6): 846-848.
62. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe. 2009;15(6):290-291.
63. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;9:CD004610.
64. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 2003;47(7): 2334-2338.
65. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986;146(6):1101-1104.
66. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011; 45(7-8):1005-1010.
67. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54(1):211-216.
68. Noren T, Wullt M, Akerlund T, Bäck E, Odenholt I, Burman LG. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother. 2006;50(9):3028-3032.
69. Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipeptide antibiotic. Ann Pharmacother. 2005;39(5):863-868.
70. Freeman J, Baines SD, Jabes D, Wilcox MH. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother. 2005;56(4):717-725.
71. Pullman J, Prieto J, Leach TS. Ramoplanin vs vancomycin in the treatment of C. difficile diarrhea: a phase 2 study [abstract K-985a]. Proceedings of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. October 30-November 2, 2004; Washington, DC.
72. Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect. 2012;18 Suppl 6:28-35.
73. Venugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis. 2012;55 Suppl 2:S71-S76.
74. Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother. 2012;56(6):3448-3452.
75. Mascio CT, Mortin LI, Howland KT, et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother. 2012;56(10): 5023-5030.
76. Saito T, Kimura S, Tateda K, et al. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J Antimicrob Chemother. 2011;66(5): 1096-1099.
77. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53(5):882-884.
78. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control. 2007;35(2):131-137.
79. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118(4 Pt 1):633-637.
80. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dise Sci. 2011; 56(1):19-26.
81. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl J Med. 2010;362(3):197-205.
82. ClinicalTrials.gov. A study of MK-3415, MK-6072, and MK-3415A in participants receiving antibiotic therapy for Clostridium difficile infection (MK-3415A-001 AM2) (MODIFY I). ClinicalTrials.gov; 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01241552. Accessed April 29, 2013.
83. ClinicalTrials.gov. A study of MK-6072 and MK-3415A in participants receiving antibiotic therapy for Clostridium difficile infection (MK-3415A-002) (MODIFY II). ClinicalTrials.gov; 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01513239. Accessed April 29, 2013.
84. Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem. 2011;286(11): 8961-8976.
85. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475-483.
86. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87(11):1106-1117.
87. Bakken JS, Borody T, Brandt LJ, et al; For Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12): 1044-1049.
88. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994-1002.
89. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5): 407-415.
90. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35(12): 1355-1369.
91. Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am. 2012;41(4):763-779.
92. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157(12):878-888.
93. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969.
94. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30(29): 4307-4309.
95. Folgia G. ACAM-CDIFF: An active vaccine against Clostridium difficile infection. Proceedings of the 10th Anaerobe Society of the Americas. July 7-10, 2010.
96. ClinicalTrials.gov. Study of a Clostridium difficile toxoid vaccine (ACAM-CDIFFTM) in subjects with Clostridium difficile infection [webpage on the Internet]. ClinicalTrials.gov; 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00772343. Accessed April 29, 2013.
97. Cappelletti E, Romano MR, Cakici OS, et al. Conjugate vaccine against Clostridium difficile. Glycoconjugate Journal. 2011;28:265.
98. Danieli E, Lay L, Proietti D, Berti F, Costantino P, Adamo R. First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. Org Lett. 2011;13(3):378-381.
99. Oberli MA, Hecht ML, Bindschädler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol. 2011;18(5):580-588.
100. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents. 2009;33 Suppl 1:S46-S50.
101. ClinicalTrials.gov. Safety and efficacy of VP20621 for prevention of recurrent Clostridium difficile infection [webpage on the Internet]. ClinicalTrials.gov; 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01259726. Accessed April 29, 2013.
102. Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Aug 2012;55 Suppl 2:S154-161.